Furthermore, 8 weeks of treating type 2 diabetic mice model with oligonol prevented dyslipidaemia, led to reduced levels of SREBP-1 expression, associated with reduced levels of the SREBP-1 target genes fatty acid synthase (FAS), acetyl-CoA carboxylase (ACC) and HMGR (Noh et al., 2011). This evidence concerns the gene SREBF1 and type 2 diabetes mellitus.